Symbol="NLTX"
AssetType="Common Stock"
Name="Neoleukin Therapeutics"
Description="Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmune disorders using protein design technology. The company is headquartered in Seattle, Washington."
CIK="1404644"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 360 - 1616 EASTLAKE AVE EAST, SEATTLE, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="29983000"
EBITDA="-52003000"
PERatio="None"
PEGRatio="None"
BookValue="1.9"
DividendPerShare="0"
DividendYield="0"
EPS="-1.02"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.27"
ReturnOnEquityTTM="-0.534"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.02"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="1.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.185"
EVToRevenue="-"
EVToEBITDA="1.31"
Beta="1.211"
num_52WeekHigh="1.219"
num_52WeekLow="0.375"
num_50DayMovingAverage="0.796"
num_200DayMovingAverage="0.652"
SharesOutstanding="44021400"
DividendDate="None"
ExDividendDate="None"
symbol="NLTX"
open="0.70"
high="0.70"
low="0.68"
price="0.69"
volume="197385.00"
latest_trading_day="2023-07-31"
previous_close="0.68"
change="0.01"
change_percent="1.3067%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="15"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="85"
Volume_recent_avg="384609"
Change_recent_avg="0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="0.3"
RSI_change="FALSE"
ADX_change="FALSE"

event="aroon_milestone_negative_10"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="85"
Aroon_momentum_negative="15"
image_negative_thumbnail_id_1="509"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0096.jpeg"
image_negative_thumbnail_id_2="1142"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0175.jpeg"
image_neutral_thumbnail_id_1="578"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_neutral_thumbnail_id_2="592"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0007.jpeg"
image_positive_thumbnail_id_1="692"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0016.jpeg"
image_positive_thumbnail_id_2="651"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0057.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1175"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
